These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 28129395

  • 1. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
    Schlott F, Steubl D, Hoffmann D, Matevossian E, Lutz J, Heemann U, Hösel V, Busch DH, Renders L, Neuenhahn M.
    PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S, Mengoli C, Pillon M, Calore E, Biasolo MA, Cusinato R, Barzon L, Messina C, Carli M, Palù G.
    Transplantation; 2012 Mar 15; 93(5):536-42. PubMed ID: 22314338
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 5. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors.
    Hoegh-Petersen M, Roa L, Liu Y, Zhou F, Ugarte-Torres A, Louie P, Fonseca K, Khan F, Russell JA, Storek J.
    Cytotherapy; 2012 Feb 15; 14(2):194-204. PubMed ID: 22149135
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
    Andreani M, Albano L, Benzaken S, Cassuto E, Jeribi A, Caramella A, Giordanengo V, Bernard G, Esnault V, Seitz-Polski B.
    Transplant Proc; 2020 Feb 15; 52(1):204-211. PubMed ID: 31889538
    [Abstract] [Full Text] [Related]

  • 7. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.
    Mikrobiyol Bul; 2016 Apr 15; 50(2):224-35. PubMed ID: 27175495
    [Abstract] [Full Text] [Related]

  • 8. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D, Hafferty J, Fulton L, Friend P, Devaney A, Loke J, Welsh KI, Handa A, Klenerman P.
    J Clin Virol; 2008 Feb 15; 41(2):92-5. PubMed ID: 18032098
    [Abstract] [Full Text] [Related]

  • 9. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
    Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, Miles CD.
    Transpl Infect Dis; 2024 Aug 15; 26(4):e14291. PubMed ID: 38708965
    [Abstract] [Full Text] [Related]

  • 10. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T, Stein M, Reinke P.
    Transplantation; 2017 Oct 15; 101(10):e315-e325. PubMed ID: 28594749
    [Abstract] [Full Text] [Related]

  • 11. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
    Krawczyk A, Ackermann J, Goitowski B, Trenschel R, Ditschkowski M, Timm J, Ottinger H, Beelen DW, Grüner N, Fiedler M.
    J Clin Virol; 2018 Oct 15; 99-100():61-66. PubMed ID: 29331844
    [Abstract] [Full Text] [Related]

  • 12. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D, Small A, Borrows R, Ball S.
    PLoS One; 2018 Oct 15; 13(3):e0193968. PubMed ID: 29558479
    [Abstract] [Full Text] [Related]

  • 13. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP.
    Biol Blood Marrow Transplant; 2015 Jan 15; 21(1):159-64. PubMed ID: 25445637
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 15. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 16. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney].
    Slavicek J, Puretić Z, Glavas-Boras S, Smalcelj R, Barisić I, Vuković J, Seso-Simić D, Slavicek V, Humar I, Kes P.
    Acta Med Croatica; 2003 Aug 01; 57(1):87-90. PubMed ID: 12876872
    [Abstract] [Full Text] [Related]

  • 17. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA.
    Transplantation; 2009 Jul 15; 88(1):77-82. PubMed ID: 19584684
    [Abstract] [Full Text] [Related]

  • 18. Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.
    Meijers RW, Litjens NH, Hesselink DA, Langerak AW, Baan CC, Betjes MG.
    Am J Transplant; 2015 Dec 15; 15(12):3143-56. PubMed ID: 26211927
    [Abstract] [Full Text] [Related]

  • 19. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, Sy S, Roa L, Khan F, Fonseca K, Russell JA, Storek J.
    Biol Blood Marrow Transplant; 2011 Apr 15; 17(4):574-85. PubMed ID: 20688181
    [Abstract] [Full Text] [Related]

  • 20. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
    Shabir S, Kaul B, Pachnio A, Banham GD, Smith H, Chand S, Jham S, Harper L, Ball S, Rahbar A, Söderberg-Nauclér C, Moss P, Borrows R.
    J Am Soc Nephrol; 2013 Oct 15; 24(10):1698-708. PubMed ID: 23847277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.